Volgen
mark-david levin
mark-david levin
Onbekend partnerschap
Geverifieerd e-mailadres voor asz.nl
Titel
Geciteerd door
Geciteerd door
Jaar
Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA …
P Moreau, M Attal, C Hulin, B Arnulf, K Belhadj, L Benboubker, MC Béné, ...
The Lancet 394 (10192), 29-38, 2019
8962019
Autologous haematopoietic stem-cell transplantation versus bortezomib–melphalan–prednisone, with or without bortezomib–lenalidomide–dexamethasone consolidation therapy, and …
M Cavo, F Gay, M Beksac, L Pantani, MT Petrucci, MA Dimopoulos, ...
The Lancet Haematology 7 (6), e456-e468, 2020
3172020
Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTOR
A Spencer, S Lentzsch, K Weisel, H Avet-Loiseau, TM Mark, I Spicka, ...
Haematologica 103 (12), 2079, 2018
2932018
COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus
L Scarfò, T Chatzikonstantinou, GM Rigolin, G Quaresmini, M Motta, ...
Leukemia 34 (9), 2354-2363, 2020
2572020
Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial
MA Dimopoulos, F Gay, F Schjesvold, M Beksac, R Hajek, KC Weisel, ...
The Lancet 393 (10168), 253-264, 2019
2412019
The prevalence and prognostic value of low muscle mass in cancer patients: a review of the literature
HN Rier, A Jager, S Sleijfer, AB Maier, MD Levin
The oncologist 21 (11), 1396-1409, 2016
2072016
Chronic lymphocytic leukemia cells impair mitochondrial fitness in CD8+ T cells and impede CAR T-cell efficacy
JAC van Bruggen, AWJ Martens, JA Fraietta, T Hofland, SH Tonino, ...
Blood, The Journal of the American Society of Hematology 134 (1), 44-58, 2019
1422019
Low muscle attenuation is a prognostic factor for survival in metastatic breast cancer patients treated with first line palliative chemotherapy
HN Rier, A Jager, S Sleijfer, J van Rosmalen, MCJM Kock, MD Levin
The Breast 31, 9-15, 2017
1422017
Hepatotoxicity of oral and intravenous voriconazole in relation to cytochrome P450 polymorphisms
MD Levin, JG den Hollander, B van der Holt, BJ Rijnders, M Van Vliet, ...
Journal of Antimicrobial Chemotherapy 60 (5), 1104-1107, 2007
1252007
Ofatumumab maintenance versus observation in relapsed chronic lymphocytic leukaemia (PROLONG): an open-label, multicentre, randomised phase 3 study
MHJ Van Oers, K Kuliczkowski, L Smolej, M Petrini, F Offner, S Grosicki, ...
The lancet oncology 16 (13), 1370-1379, 2015
1192015
Maintenance with daratumumab or observation following treatment with bortezomib, thalidomide, and dexamethasone with or without daratumumab and autologous stem-cell transplant …
P Moreau, C Hulin, A Perrot, B Arnulf, K Belhadj, L Benboubker, MC Bene, ...
The Lancet Oncology 22 (10), 1378-1390, 2021
1122021
Melphalan, prednisone, and lenalidomide versus melphalan, prednisone, and thalidomide in untreated multiple myeloma
S Zweegman, B van der Holt, UH Mellqvist, M Salomo, GMJ Bos, ...
Blood, The Journal of the American Society of Hematology 127 (9), 1109-1116, 2016
1102016
Fixed-duration ibrutinib-venetoclax in patients with chronic lymphocytic leukemia and comorbidities
AP Kater, C Owen, C Moreno, G Follows, T Munir, MD Levin, O Benjamini, ...
NEJM evidence 1 (7), EVIDoa2200006, 2022
1062022
Distinct immune composition in lymph node and peripheral blood of CLL patients is reshaped during venetoclax treatment
I de Weerdt, T Hofland, R de Boer, JA Dobber, J Dubois, ...
Blood advances 3 (17), 2642-2652, 2019
992019
First-line venetoclax combinations in chronic lymphocytic leukemia
B Eichhorst, CU Niemann, AP Kater, M Fürstenau, J Von Tresckow, ...
New England Journal of Medicine 388 (19), 1739-1754, 2023
842023
Addition of bevacizumab to chemotherapy in acute myeloid leukemia at older age: a randomized phase 2 trial of the Dutch-Belgian Cooperative Trial Group for Hemato-Oncology …
GJ Ossenkoppele, G Stussi, J Maertens, K van Montfort, BJ Biemond, ...
Blood, The Journal of the American Society of Hematology 120 (24), 4706-4711, 2012
782012
COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study
T Chatzikonstantinou, A Kapetanakis, L Scarfò, G Karakatsoulis, D Allsup, ...
Leukemia 35 (12), 3444-3454, 2021
752021
Incidence of voriconazole hepatotoxicity during intravenous and oral treatment for invasive fungal infections
JG den Hollander, C van Arkel, BJ Rijnders, PJ Lugtenburg, S de Marie, ...
Journal of Antimicrobial Chemotherapy 57 (6), 1248-1250, 2006
692006
Phase 1/2 study of lenalidomide combined with low-dose cyclophosphamide and prednisone in lenalidomide-refractory multiple myeloma
IS Nijhof, LE Franssen, MD Levin, GMJ Bos, A Broijl, SK Klein, HR Koene, ...
Blood, The Journal of the American Society of Hematology 128 (19), 2297-2306, 2016
612016
New approaches and treatment combinations for the management of chronic myeloid leukemia
PE Westerweel, PAW Te Boekhorst, MD Levin, JJ Cornelissen
Frontiers in oncology 9, 665, 2019
592019
Het systeem kan de bewerking nu niet uitvoeren. Probeer het later opnieuw.
Artikelen 1–20